INTO - Inhalation Together, the unique alliance in the field of inhalation development services established by DFE Pharma, Harro Höfliger and STERLING S.P.A., has been nominated for the 2026 Prix Galien Bridges Awards in the Best Enabling Technology for Medical Innovation category.

The nomination recognizes collaborative research into an inhalable, spray-dried formulation of semaglutide. As part of the research, trehalose from DFE Pharma was used as a stabilizing excipient bulking agent, alongside L-leucine to improve aerosol performance. Preclinical results showed that the formulation achieved rapid systemic absorption and a reduction in body weight comparable to subcutaneous administration.

Overall, these findings demonstrate that spray-dried semaglutide inhalation powders can achieve efficient pulmonary delivery while maintaining peptide integrity and biological activity, supporting inhaled semaglutide as a promising non-invasive alternative for systemic GLP-1 therapy.